---
title: "Mounjaro (tirzepatide) in type 2 diabetes: Clinical trials questions"
description: "Clinical trials questions on Mounjaro (tirzepatide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How much does Mounjaro lower A1C in type 2 diabetes trials? How much does Mounjaro alone lower A1C and weight vs placebo (SURPASS-1)? Mounjaro vs Ozempic 1 mg: which lowers A1C and weight more (SURPASS-2)? Mounjaro vs insulin degludec (Tresiba): how do A1C and weight compare (SURPASS-3)? 9 further questions follow. 13 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide) in type 2 diabetes: Clinical trials questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)

Questions that apply to every indication of Mounjaro are on [Mounjaro (tirzepatide), all indications](https://www.evicenter.com/medical-information/mounjaro).

## Study results

<a id="mounjaro-a1c-across-trials"></a>

### How much does Mounjaro lower A1C in type 2 diabetes trials?

> “Panel of bar charts showing the mean change in A1C from baseline for pediatric and adult patients with type 2 diabetes. SURPASS-PEDS studied Mounjaro as add-on to metformin and/or basal insulin vs placebo over 30 weeks in pediatric patients 10 years of age and older with type 2 diabetes. The mean baseline A1C was 8.2%, 7.9%, 8.1%, and 8.0% for Mounjaro 5 mg, Mounjaro 10 mg, pooled Mounjaro (5 mg and 10 mg), and placebo, respectively. Patients in the Mounjaro 5 mg group (n=32) had a -1.9% change from baseline. Patients in the Mounjaro 10 mg group (n=33) had a -2.2% change from baseline. Patients in the pooled Mounjaro group (n=65) had a -2.0% change from baseline. Patients in the placebo group (n=34) had a -0.2 percent change from baseline.
>
> SURPASS-1 through -5 evaluated the mean change in A1C from baseline in adult patients with type 2 diabetes.
>
> SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline A1C was 8.0%, 7.9%, 7.9%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients in the Mounjaro 5 mg group (n=121) had a -1.8% change from baseline. Patients in the Mounjaro 10 mg group (n=121) had a -1.7% change from baseline. Patients in the Mounjaro 15 mg group (n=120) had a -1.7% change from baseline. Patients in the placebo group (n=113) had a -0.1 percent change from baseline.
>
> SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. Ozempic 2 mg injection was not available at the time of the study. The mean baseline A1C was 8.3% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg. Patients taking Mounjaro 5 mg (n=470) had a -2.0% change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -2.2% change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -2.3% change from baseline. Patients taking Ozempic 1 mg (n=468) had a -1.9% change from baseline.
>
> SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline A1C was 8.2%, 8.2%, 8.2%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -1.9% change from baseline. Patients taking Mounjaro 10 mg (n=360) had a -2.0% change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -2.1% change from baseline. Patients taking Tresiba (n=359) had a -1.3% change from baseline.
>
> SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline A1C was 8.5%, 8.6%, 8.5%, and 8.5% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -2.3% change from baseline.
>
> Patients taking Mounjaro 15 mg (n=337) had a -2.4% change from baseline. Patients taking insulin glargine (n=998) had a -1.4% change from baseline.
>
> SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline A1C was 8.3%, 8.4%, 8.2%, and 8.4% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -2.4% change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -2.3% change from baseline. Patients taking placebo (n=119) had a -0.9% change from baseline.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Panel%20of%20bar%20charts%20showing,a%20%2D0.9%25%20change%20from%20baseline.)

On the page, select: Image description

> “Data represent least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Data%20represent%20least%2Dsquares%20mean%20from,baseline%20value%20and%20other%20stratification)

> “<sup>a</sup>Pediatric patients aged 10 to <18 years.<sup>1,2</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=patients%20aged%2010%20to%20%3C18)

> “<sup>b</sup>At week 52, 26% of adult patients randomized to Tresiba achieved the fasting serum glucose target of <90 mg/dL, and the mean daily Tresiba dose was 49 U (0.5 U/kg).<sup>1</sup>
>
> <sup>c</sup>At week 52, 30% of adult patients randomized to insulin glargine achieved the fasting serum glucose target of <100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U/kg).<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=week%2052%2C%2026%25%20of%20adult,dose%20was%2044%20U%20%280.5)

> “<sup>d</sup>p<0.001 for superiority vs comparator, adjusted for multiplicity.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=for%20superiority%20vs%20comparator%2C%20adjusted%20for)

> “<sup>e</sup>p<0.05 for superiority vs Ozempic 1 mg, adjusted for multiplicity.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=for%20superiority%20vs%20Ozempic%201%20mg%2C%20adjusted%20for)

> “Ozempic 2 mg injection was not available at time of SURPASS-2 study.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Ozempic%202%20mg%20injection%20was%20not%20available%20at%20time%20of%20SURPASS%2D2%20study.)

Note: The figure description does not mark which results carry footnotes d and e; the Prescribing Information tables for SURPASS-1 through -5 and SURPASS-PEDS give each difference from comparator with its 95% CI and p-value.

<a id="mounjaro-surpass1-monotherapy"></a>

### How much does Mounjaro alone lower A1C and weight vs placebo (SURPASS-1)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2D1%20%28NCT03954834%29%20was%20a%2040%2Dweek,mg%2C%20or%20placebo%20once%20weekly.)

> “Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity.
>
>
>
>
> d Analyzed using logistic regression adjusted for baseline value and other stratification factors.
>
>
> 	Placebo	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 15 mg
> Modified Intent-to-Treat (mITT) Population (N)a	113	121	121	120
> HbA1c (%)				
>      Baseline (mean)	8.1	8.0	7.9	7.9
>      Change at Week 40b	-0.1	-1.8	-1.7	-1.7
>      Difference from placebob (95% CI)	--	-1.7c
> (-2.0, -1.4)	-1.6c
> (-1.9, -1.3)	-1.6c
> (-1.9, -1.3)
> Patients (%) achieving HbA1c <7%d	23	82c	85c	78c
> Fasting Serum Glucose (mg/dL)				
>      Baseline (mean)	155	154	153	154
>      Change at Week 40b	4	-40	-40	-39
>      Difference from
>      placebob (95% CI)	--	-43c
> (-55, -32)	-43c
> (-55, -32)	-42c
> (-54, -30)
> Body Weight (kg)				
>      Baseline (mean)	84.5	87.0	86.2	85.5
>      Change at Week 40b	-1.0	-6.3	-7.0	-7.8
>      Difference from
>      placebob (95% CI)	--	-5.3c
> (-6.8, -3.9)	-6.0c
> (-7.4, -4.6)	-6.8c
> (-8.3, -5.4)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%204%3A%20Results%20at%20Week,%28%2D8.3%2C%20%2D5.4%29)

Note: Table 4 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

<a id="mounjaro-surpass2-vs-ozempic"></a>

### Mounjaro vs Ozempic 1 mg: which lowers A1C and weight more (SURPASS-2)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1,879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2D2%20%28NCT03987919%29%20was%20a%2040%2Dweek,semaglutide%201%20mg%20once%20weekly.)

> “Treatment with MOUNJARO 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1 mg once weekly (see Table 5 and Figure 2).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Treatment%20with%20MOUNJARO%2010%20mg,Table%205%20and%20Figure%202%29.)

> “Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.05 (two-sided) for superiority versus semaglutide, adjusted for multiplicity.
>
>
>
>
> d p<0.001 (two-sided) for superiority versus semaglutide, adjusted for multiplicity.
>
>
>
>
> e Analyzed using logistic regression adjusted for baseline value and other stratification factors.
>
>
>
>
> f p<0.01 (two-sided) for superiority versus semaglutide, adjusted for multiplicity.
>
>
> 	Semaglutide
> 1 mg	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 15 mg
> Modified Intent-to-Treat (mITT) Population (N)a	468	470	469	469
> HbA1c (%)				
>      Baseline (mean)	8.3	8.3	8.3	8.3
>      Change at Week 40b	-1.9	-2.0	-2.2	-2.3
>      Difference from semaglutideb (95% CI)	--	-0.2c
> (-0.3, -0.0)	-0.4d
> (-0.5, -0.3)	-0.5d
> (-0.6, -0.3)
> Patients (%) achieving HbA1c <7%e	79	82	86f	86f
> Fasting Serum Glucose (mg/dL)				
>      Baseline (mean)	171	174	174	172
>      Change at Week 40b	-49	-55	-59	-60
> Body Weight (kg)				
>      Baseline (mean)	93.7	92.5	94.8	93.8
>      Change at Week 40b	-5.7	-7.6	-9.3	-11.2
>      Difference from semaglutideb (95% CI)	--	-1.9c
> (-2.8, -1.0)	-3.6d
> (-4.5, -2.7)	-5.5d
> (-6.4, -4.6)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%205%3A%20Results%20at%20Week,%28%2D6.4%2C%20%2D4.6%29)

> “Ozempic 2 mg injection was not available at time of SURPASS-2 study.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Ozempic%202%20mg%20injection%20was%20not%20available%20at%20time%20of%20SURPASS%2D2%20study.)

Note: Table 5 columns are semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order. The Mounjaro HCP site names the SURPASS-2 comparator Ozempic 1 mg. These results apply to SURPASS-2 and its semaglutide 1 mg dose only.

<a id="mounjaro-surpass3-vs-degludec"></a>

### Mounjaro vs insulin degludec (Tresiba): how do A1C and weight compare (SURPASS-3)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1,444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10 units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of <90 mg/dL, and the mean daily insulin degludec dose was 49 U (0.5 U per kilogram).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2D3%20%28NCT03882970%29%20was%20a%2052%2Dweek,U%20%280.5%20U%20per%20kilogram%29.)

> “Table 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (two-sided) for superiority versus insulin degludec, adjusted for multiplicity.
>
>
>
>
> d Analyzed using logistic regression adjusted for baseline value and other stratification factors.
>
>
> 	Insulin Degludec	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 15 mg
> Modified Intent-to-Treat (mITT)a Population (N)	359	358	360	358
> HbA1c (%)				
>      Baseline (mean)	8.1	8.2	8.2	8.2
>      Change at Week 52b	-1.3	-1.9	-2.0	-2.1
>      Difference from insulin degludecb (95% CI)	--	-0.6c
> (-0.7, -0.5)	-0.8c
> (-0.9, -0.6)	-0.9c
> (-1.0, -0.7)
> Patients (%) achieving HbA1c <7%d	58	79c	82c	83c
> Fasting Serum Glucose (mg/dL)				
>      Baseline (mean)	167	172	170	168
>      Change at Week 52b	-51	-47	-50	-54
> Body Weight (kg)				
>      Baseline (mean)	94.0	94.4	93.8	94.9
>      Change at Week 52b	1.9	-7.0	-9.6	-11.3
>      Difference from insulin degludecb (95% CI)	--	-8.9c
> (-10.0, -7.8)	-11.5c
> (-12.6, -10.4)	-13.2c
> (-14.3, -12.1)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%206%3A%20Results%20at%20Week,%28%2D14.3%2C%20%2D12.1%29)

Note: Table 6 columns are insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

<a id="mounjaro-surpass4-vs-glargine"></a>

### Mounjaro vs insulin glargine: how do A1C and weight compare (SURPASS-4)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased CV risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2D4%20%28NCT03730662%29%20was%20a%20104%2Dweek,%2854%25%29%20and%2For%20SGLT2%20inhibitors%20%2825%25%29.)

> “Insulin glargine was initiated at 10 U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of <100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U per kilogram).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Insulin%20glargine%20was%20initiated%20at,U%20%280.5%20U%20per%20kilogram%29.)

> “Table 7: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (two-sided) for superiority versus insulin glargine, adjusted for multiplicity.
>
>
>
>
> d Analyzed using logistic regression adjusted for baseline value and other stratification factors.
>
>
> 	Insulin Glargine	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 15 mg
> Modified Intent-to-Treat (mITT) Population (N)a	998	328	326	337
> HbA1c (%)				
>      Baseline (mean)	8.5	8.5	8.6	8.5
>      Change at Week 52b	-1.4	-2.1	-2.3	-2.4
>      Difference from insulin glargineb (95% CI)	--	-0.7c
> (-0.9, -0.6)	-0.9c
> (-1.1, -0.8)	-1.0c
> (-1.2, -0.9)
> Patients (%) achieving HbA1c <7%d	49	75c	83c	85c
> Fasting Serum Glucose (mg/dL)				
>      Baseline (mean)	168	172	176	174
>      Change at Week 52b	-49	-44	-50	-55
> Body Weight (kg)				
>      Baseline (mean)	90.2	90.3	90.6	90.0
>      Change at Week 52b	1.7	-6.4	-8.9	-10.6
>      Difference from insulin glargineb (95% CI)	--	-8.1c
> (-8.9, -7.3)	-10.6c
> (-11.4, -9.8)	-12.2c
> (-13.0, -11.5)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%207%3A%20Results%20at%20Week,%28%2D13.0%2C%20%2D11.5%29)

Note: Table 7 columns are insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

<a id="mounjaro-surpass5-with-basal-insulin"></a>

### How well does Mounjaro work when added to basal insulin (SURPASS-5)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 adult patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting <100 mg/dL.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2D5%20%28NCT04039503%29%20was%20a%2040%2Dweek,glucose%20values%2C%20targeting%20%3C100%20mg%2FdL.)

> “The mean dose of insulin glargine at baseline was 34, 32, 35, and 33 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c ≤8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20mean%20dose%20of%20insulin,MOUNJARO%205%20mg%2C%2010%20mg%2C%2015%20mg%2C%20and%20placebo%2C%20respectively.)

> “Table 8: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity.
>
>
>
>
> d Analyzed using logistic regression adjusted for baseline value and other stratification factors.
>
>
> 	Placebo	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 15 mg
> Modified Intent-to-Treat (mITT) Population (N)a	119	116	118	118
> HbA1c (%)				
>      Baseline (mean)	8.4	8.3	8.4	8.2
>      Change at Week 40b	-0.9	-2.1	-2.4	-2.3
>      Difference from placebob (95% CI)	--	-1.2c
> (-1.5, -1.0)	-1.5c
> (-1.8, -1.3)	-1.5c
> (-1.7, -1.2)
> Patients (%) achieving HbA1c <7%d	35	87c	90c	85c
> Fasting Serum Glucose (mg/dL)				
>      Baseline (mean)	164	163	163	160
>      Change at Week 40b	-39	-58	-64	-63
>      Difference from placebob (95% CI)	--	-19c
> (-27, -11)	-25c
> (-32, -17)	-23c
> (-31, -16)
> Body Weight (kg)				
>      Baseline (mean)	94.2	95.8	94.6	96.0
>      Change at Week 40b	1.6	-5.4	-7.5	-8.8
>      Difference from placebob (95% CI)	--	-7.1c
> (-8.7, -5.4)	-9.1c
> (-10.7, -7.5)	-10.5c
> (-12.1, -8.8)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%208%3A%20Results%20at%20Week,%28%2D12.1%2C%20%2D8.8%29)

Note: Table 8 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

<a id="mounjaro-weight-loss-type-2-diabetes"></a>

### How much weight do adults lose on Mounjaro in type 2 diabetes trials?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Mounjaro is not indicated for weight loss.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Mounjaro%20is%20not%20indicated%20for%20weight%20loss.)

> “*In SURPASS-PEDS, percent change in BMI was a secondary endpoint. In SURPASS-1 through -5, change in weight was a secondary endpoint.<sup>1,2</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=%2AIn%20SURPASS%2DPEDS%2C%20percent%20change%20in,in%20weight%20was%20a%20secondary)

> “SURPASS-1 through -5 evaluated the mean change in weight from baseline in adult patients with type 2 diabetes.
>
> SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline weight was 191.8 lb, 190.0 lb, 188.5 lb, and 186.3 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=121) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=121) had a -15 lb change from baseline. Patients taking Mounjaro 15 mg (n=120) had a -17 lb change from baseline. Patients taking placebo (n=113) had a -2 lb change from baseline.
>
> SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. Ozempic 2 mg injection was not available at the time of the study. The mean baseline weight was 203.9 lb, 209.0 lb, 206.8 lb, and 206.6 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg, respectively. Patients taking Mounjaro 5 mg (n=470) had a -17 lb change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -25 lb change from baseline. Patients taking Ozempic 1 mg (n=468) had a -13 lb change from baseline.
>
> SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline weight was 208.1 lb, 206.8 lb, 209.2 lb, and 207.2 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -15 lb change from baseline. Patients taking Mounjaro 10 mg (n=360) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -25 lb change from baseline. Patients taking Tresiba (n=359) had a +4 lb change from baseline.
>
> SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline weight was 199.1 lb, 199.7 lb, 198.4 lb, and 198.9 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -20 lb change from baseline. Patients taking Mounjaro 15 mg (n=337) had a -23 lb change from baseline. Patients taking insulin glargine (n=998) had a +4 lb change from baseline.
>
> SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline weight was 211.2 lb, 208.6 lb, 211.6 lb, and 207.7 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -12 lb change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -17 lb change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -19 lb change from baseline. Patients taking placebo (n=119) had a +4 lb change from baseline.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=SURPASS%2D1%20through%20%2D5%20evaluated%20the%20mean%20change%20in%20weight,%28n%3D119%29%20had%20a%20%2B4%20lb%20change%20from%20baseline.)

On the page, select: Image description

> “Data are least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Data%20are%20least%2Dsquares%20mean%20from%20ANCOVA%20adjusted%20for%20baseline%20value%20and%20other)

> “<sup>b</sup>p<0.001 for superiority vs comparator, adjusted for multiplicity.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=bp%3C0.001%20for%20superiority%20vs%20comparator%2C%20adjusted%20for%20multiplicity.1)

> “<sup>c</sup>p<0.05 for superiority vs comparator, adjusted for multiplicity.<sup>1</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=cp%3C0.05%20for%20superiority%20vs%20comparator%2C%20adjusted%20for%20multiplicity.1)

Note: The image description does not mark which results carry footnotes b and c. The Prescribing Information tables for SURPASS-1 through -5 give the same weight changes in kilograms with the difference from comparator and its 95% CI.

<a id="mounjaro-peds-a1c-bmi"></a>

### How much does Mounjaro lower A1C and BMI in children and teens (SURPASS-PEDS)?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=SURPASS%2DPEDS%20%28NCT05260021%29%20was%20a%2030%2Dweek,once%20weekly%20as%20add%2Don%20therapy.)

> “Patients had a mean age of 15 years, and 61% were female. The mean duration of type 2 diabetes mellitus was 2.4 years, mean HbA1c was 8.0%, mean weight was 97 kg, and the mean baseline BMI was 35 kg/m2. Overall, 58% were White, 11% were Black or African American, 6% were Asian, 20% were American Indian or Alaska Native, and 5% were other races; 66% identified as Hispanic or Latino ethnicity.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Patients%20had%20a%20mean%20age%20of%2015,as%20Hispanic%20or%20Latino%20ethnicity.)

> “Table 9: Results at Week 30 in a Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
>
> a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 6%, 0%, and 0% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. At Week 30 the HbA1c endpoint was missing for 6%, 9%, and 18% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. Missing Week 30 data were imputed using multiple imputation with placebo wash-out or with assumption of missing at random.
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity.
>
>
>
>
> d Response in (%) is calculated by combining proportion of participants achieving target in imputed datasets using Rubin's rule.
>
>
>
>
> e p<0.01 (two-sided) for superiority versus placebo, adjusted for multiplicity.
>
>
>
>
> f Any missing values at baseline were imputed as missing at random.
>
>
> 	Placebo	MOUNJARO
> 5 mg	MOUNJARO
> 10 mg	MOUNJARO
> 5 mg/10 mg pooled
> Modified Intent-to-Treat (mITT) Population (N)a	34	32	33	65
> HbA1c (%)				
>       Baseline (mean)	8.0	8.2	7.9	8.1
>       Change at Week 30b	-0.2	-1.9	-2.2	-2.0
>       Difference from placebob (95% CI)	--	-1.7c
> (-2.4, -1.0)	-2.0c
> (-2.7, -1.3)	-1.8c
> (-2.4, -1.2)
> Patients (%) with HbA1c ≤6.5% at Week 30d	28	68c	81c	75c
> Fasting Serum Glucose (mg/dL)				
>       Baseline (mean)	156f	148f	152f	150f
>       Change at Week 30b	-5	-35	-51	-43
>       Difference from placebob (95% CI)	--	-30e
> (-53, -8)	-46c
> (-68, -24)	-38c
> (-57, -19)
> BMI (kg/m2)				
>       Baseline (mean)	34.7	33.9	37.7	35.8
>       Percent Change at Week 30b	-0.5	-6.9	-10.8	-8.8
>       Difference from placebo (%)b (95% CI)	--	-6.4c
> (-9.5, -3.2)	-10.3c
> (-13.5, -7.1)	-8.3c
> (-11.0, -5.6)”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Table%209%3A%20Results%20at%20Week,%28%2D11.0%2C%20%2D5.6%29)

> “Treatment regimen estimand; mITT population.<sup>1,2</sup>”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Treatment%20regimen%20estimand%3B%20mITT)

> “Mounjaro is not indicated for weight loss.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Mounjaro%20is%20not%20indicated%20for%20weight%20loss.)

> “In SURPASS-PEDS, percent change in BMI was a secondary endpoint. The primary endpoint of SURPASS-PEDS was change in A1C from baseline at 30 weeks.<sup>1,2</sup>”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=In%20SURPASS%2DPEDS%2C%20percent%20change%20in,A1C%20from%20baseline%20at%2030)

Note: Table 9 columns are placebo, MOUNJARO 5 mg, 10 mg, and the 5 mg/10 mg pooled group, in that order.

<a id="mounjaro-peds-52-weeks"></a>

### Do A1C and BMI reductions on Mounjaro last 52 weeks in children (SURPASS-PEDS)?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The 30-week double-blind period was followed by a 22-week open-label extension in which all participants received Mounjaro + metformin and/or basal insulin. In the open-label extension, participants in the placebo arm initiated Mounjaro 2.5 mg for 4 weeks and then continued on Mounjaro 5 mg for the remainder of the study (up to week 52).<sup>2</sup>”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=The%2030%2Dweek%20double%2Dblind%20period%20was,the%20study%20%28up%20to%20week)

> “A line graph showing the change in A1C over time from baseline to 52 weeks for Mounjaro vs placebo. At week 0, the mean baseline A1C was 8.0%. At week 52, patients taking Mounjaro 5 mg (n=32) had a -2.1 percent change from baseline; patients taking Mounjaro 10 mg (n=33) had a -2.3 percent change from baseline; patients taking pooled Mounjaro (5 mg and 10 mg) (n=65) had a -2.2 percent change from baseline; and patients taking placebo who then switched to Mounjaro 5 mg (n=34) at week 30 had a -1.5 percent change from baseline to week 52.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=A%20line%20graph%20showing%20the,from%20baseline%20to%20week%2052.)

On the page, select: Image description

> “A line graph showing the percent change in body mass index over time from baseline to 52 weeks for Mounjaro vs placebo. At week 0, the mean baseline body mass index was 35 kilograms per square meter. At week 52, patients taking Mounjaro 5 mg (n=32) had a -8.9 percent change from baseline; patients taking Mounjaro 10 mg (n=33) had a -15.1 percent change from baseline; patients taking pooled Mounjaro (5 mg and 10 mg) (n=65) had a -12.0 percent change from baseline; and patients taking placebo who then switched to Mounjaro 5 mg (n=34) at week 30 had a -4.8 percent change from baseline to week 52.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=A%20line%20graph%20showing%20the%20percent,from%20baseline%20to%20week%2052.)

On the page, select: Image description

> “Analyses based on efficacy estimand data (on-treatment efficacy without the influence of rescue therapy) and may not represent a real-world setting.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Analyses%20based%20on%20efficacy%20estimand,not%20represent%20a%20real%2Dworld%20setting.)

> “<sup>a</sup>Efficacy estimand; mITT population.<sup>2
> b</sup>Not controlled for type I error.<sup>2</sup>”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=controlled%20for%20type%20I)

> “Mounjaro is not indicated for weight loss.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Mounjaro%20is%20not%20indicated%20for%20weight%20loss.,-In%20SURPASS%2DPEDS%2C%20the)

<a id="mounjaro-surpass-early-a1c"></a>

### How much does Mounjaro lower A1C in early type 2 diabetes (SURPASS-EARLY)?

Applies to: Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

> “SURPASS-EARLY was a randomized, open-label, parallel-group, phase 4 study to evaluate the long-term efficacy and safety of Mounjaro 15 mg or MTD + metformin compared with ICC + metformin in 794 adults diagnosed with type 2 diabetes within 0-4 years, whose blood glucose was inadequately controlled with diet and exercise and metformin (≥1500 mg/day or maximum tolerated dose for at least 90 days before baseline), alone. Metformin was to be continued as background therapy.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=SURPASS%2DEARLY%20was%20a%20randomized%2C%20open%2Dlabel%2C,to%20be%20continued%20as%20background)

> “Primary endpoint: change in A1C from baseline to 104 weeks.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Primary%20endpoint%3A%20change%20in%20A1C%20from%20baseline%20to%20104)

> “At the primary endpoint (104 weeks), patients taking Mounjaro 15 mg or maximum tolerated dose plus metformin had a mean change in A1C of -2.0% and a final mean of 5.6%, and patients undergoing intensified conventional care plus metformin had a mean change in A1C of -1.3% and a final mean of 6.4%.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=At%20the%20primary%20endpoint%20%28104,a%20final%20mean%20of%206.4%25.)

> “Mean A1C over time from baseline to 104 weeks is shown here. The final A1C value at 104 weeks was 5.6% for Mounjaro 15 milligrams or MTD and 6.4% for ICC. These correspond to mean changes of A1C of minus 2% for Mounjaro and minus 1.3% for ICC using treatment-regimen estimand, which was the primary outcome of the study.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Mean%20A1C%20over%20time%20from,primary%20outcome%20of%20the%20study.)

On the page, select: Video transcript

> “A line graph that shows the mean A1C for Mounjaro 15 mg or maximum tolerated dose plus metformin and for intensified conventional care plus metformin from baseline to 104 weeks. 383 patients took Mounjaro 15 mg or maximum tolerated dose plus metformin, and 385 patients underwent intensified conventional care plus metformin. At the start of treatment, both treatment groups had a mean baseline A1C of 7.8%.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=A%20line%20graph%20that%20shows,mean%20baseline%20A1C%20of%207.8%25.)

On the page, select: Image description

> “Analysis based on efficacy estimand data (on-treatment efficacy without the influence of rescue therapy or prohibited medication) and may not represent a real-world setting. Post-baseline A1C data represent a model-based estimate derived from an MMRM model adjusting for baseline A1C, geographic region, age, and treatment-by-time interaction.3”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Analysis%20based%20on%20efficacy%20estimand,region%2C%20age%2C%20and%20treatment%2Dby%2Dtime%20interaction.3)

> “aAnalysis based on treatment-regimen estimand data (in-trial efficacy regardless of treatment discontinuation or initiation of antihyperglycemic rescue or prohibited medication). n=398 for Mounjaro 15 mg or MTD; n=396 for ICC. Data represent a model-based estimate derived from an ANCOVA model adjusting for baseline A1C, treatment, geographic region, and age.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=aAnalysis%20based%20on%20treatment%2Dregimen%20estimand,A1C%2C%20treatment%2C%20geographic%20region%2C%20and)

Note: The clinical data page places an efficacy-estimand note after the graph description, while the video transcript identifies the -2.0% and -1.3% changes as treatment-regimen estimand results (the primary outcome). The page gives no between-group difference, confidence interval, or p-value. SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site, which cites Del Prato et al., Ann Intern Med 2026; the Mounjaro Prescribing Information does not describe this trial.

<a id="mounjaro-surpass-early-weight"></a>

### How much weight did people lose on Mounjaro in SURPASS-EARLY?

Applies to: Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

> “Mounjaro is not indicated for weight loss.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Mounjaro%20is%20not%20indicated%20for%20weight%20loss.,-Change%20in%20weight)

> “Change in weight was a key secondary endpoint.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Change%20in%20weight%20was%20a%20key%20secondary)

> “At the primary endpoint (104 weeks), patients taking Mounjaro 15 mg or maximum tolerated dose plus metformin had a mean change in weight of -34.8 lb (-30.5 lb using treatmentregimen estimand) and patients undergoing intensified conventional care plus metformin had a mean change in weight of -14.3 lb (-13.0 lb using treatment-regimen estimand).”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=At%20the%20primary%20endpoint%20%28104%20weeks%29%2C%20patients%20taking%20Mounjaro%2015%20mg%20or%20maximum%20tolerated%20dose%20plus%20metformin%20had%20a%20mean%20change%20in%20weight%20of%20%2D34.8%20lb%20%28%2D30.5%20lb%20using%20treatmentregimen%20estimand%29%20and%20patients%20undergoing%20intensified%20conventional%20care%20plus%20metformin%20had%20a%20mean%20change%20in%20weight%20of%20%2D14.3%20lb%20%28%2D13.0%20lb%20using%20treatment%2Dregimen%20estimand%29.,-Analyses%20based%20on)

> “A line graph that shows the mean change in weight for Mounjaro 15 mg or maximum tolerated dose plus metformin and for intensified conventional care plus metformin from baseline to 104 weeks. 392 patients took Mounjaro 15 mg or maximum tolerated dose plus metformin and 391 patients underwent intensified conventional care plus metformin. At the start of treatment, the mean baseline weight was 220.7 lb.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=A%20line%20graph%20that%20shows%20the%20mean%20change,baseline%20weight%20was%20220.7%20lb.)

On the page, select: Image description

> “Analyses based on efficacy estimand data (on-treatment efficacy without the influence of rescue therapy or prohibited medication) and may not represent a real-world setting.<sup>3</sup> Post-baseline change in weight represents a model-based estimate derived from an MMRM model adjusting for baseline weight, geographic region, age, baseline A1C group, and treatment-by-time interaction.3,4”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Analyses%20based%20on%20efficacy%20estimand,A1C%20group%2C%20and%20treatment%2Dby%2Dtime%20interaction.3%2C4)

> “aAnalysis based on treatment-regimen estimand data (in-trial efficacy regardless of treatment discontinuation or initiation of antihyperglycemic rescue or prohibited medication). n=398 for Mounjaro 15 mg or MTD; n=396 for ICC. Data represent a model-based estimate derived from an ANCOVA model adjusting for baseline weight, treatment, baseline A1C group, geographic region, and age.<sup>3,4</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=and%20treatment%2Dby%2Dtime%20interaction.3%2C4-,aAnalysis%20based%20on%20treatment%2Dregimen%20estimand%20data%20%28in%2Dtrial%20efficacy%20regardless%20of,A1C%20group%2C%20geographic%20region%2C%20and)

Note: SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site; the Mounjaro Prescribing Information does not describe this trial.

<a id="mounjaro-surpass-early-comparator"></a>

### Mounjaro SURPASS-EARLY: what treatments did the comparison group receive?

Applies to: Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

> “Participants in the ICC arm received ICC + metformin. ICC was defined as any glucose-lowering medication, tirzepatide excluded, used in clinical practice and supported by treatment guidelines, including intensified monitoring of usual care every 3 months with adjustments to therapy and additional monitoring as needed.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Participants%20in%20the%20ICC%20arm,therapy%20and%20additional%20monitoring%20as)

> “To the ICC arm, study investigators faced no cost or insurance restrictions when selecting T2D medications to prescribe. Guideline-recommended adjustments to therapy included escalation of doses and adding or switching T2D medications.<sup>3,4</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=To%20the%20ICC%20arm%2C%20study,and%20adding%20or%20switching%20T2D)

> “From randomization to week 104, the percentage of patients taking GLP-1 receptor agonists: semaglutide (injectable) (55.6%), semaglutide (oral) (18.2%), dulaglutide (11.8%). The percentage of patients taking SGLT2 inhibitors: empagliflozin (6.9%), dapagliflozin (6.1%), dapagliflozin propanediol monohydrate (2.6%), ertugliflozin (0.9%), and canagliflozin hemihydrate (0.3%). The percentage of patients taking sulfonylureas: gliclazide (2.0%) and glimepiride (1.2%). The percentage of patients taking DPP-4 inhibitors: linagliptin (0.9%), vildagliptin (0.6%), sitagliptin (0.3%), and sitagliptin phosphate (0.3%). The percentage of patients taking insulin: insulin glargine (2.0%) and insulin degludec (0.6%).<sup>4</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=From%20randomization%20to%20week%20104%2C,glargine%20%282.0%25%29%20and%20insulin%20degludec)

<a id="mounjaro-surpass-early-composite"></a>

### How many people on Mounjaro met the combined A1C, weight, and hypoglycemia goal (SURPASS-EARLY)?

Applies to: Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

> “A graphic that shows the percentage of patients who had the composite endpoint of A1C less than or equal to 6.5%, weight reduction greater than or equal to 10%, and no clinically significant or severe hypoglycemia with Mounjaro 15 mg or maximum tolerated dose plus metformin or intensified conventional care plus metformin. 54.2% of patients had the composite endpoint with Mounjaro 15 mg or maximum tolerated dose plus metformin and 21.1% with intensified conventional care plus metformin.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=A%20graphic%20that%20shows%20the,with%20intensified%20conventional%20care%20plus%20metformin.)

On the page, select: Image description

> “Additional secondary endpoints were the proportion of participants who had the composite endpoint (A1C ≤6.5%, weight reduction ≥10%, and no clinically significant or severe hypoglycemia) at week 104, and change in insulin resistance from baseline to week 104.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Additional%20secondary%20endpoints%20were%20the,resistance%20from%20baseline%20to%20week)

> “<sup>a</sup>Clinically significant hypoglycemia defined as plasma glucose <54 mg/dL. Severe hypoglycemia defined as episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=significant%20hypoglycemia%20defined%20as%20plasma,carbohydrate%2C%20glucagon%2C%20or%20other%20resuscitative)

> “Analysis based on treatment-regimen estimand data (in-trial efficacy regardless of treatment discontinuation or initiation of antihyperglycemic rescue or prohibited medication).<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Analysis%20based%20on%20treatment%2Dregimen%20estimand%20data%20%28in%2Dtrial%20efficacy%20regardless%20of,of%20antihyperglycemic%20rescue%20or%20prohibited)

> “Endpoint measures are from a logistic regression model using imputed data.<sup>3</sup>”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=Endpoint%20measures%20are%20from%20a%20logistic%20regression%20model%20using%20imputed)

> “Mounjaro is not indicated for weight loss.”

Source: [MOUNJARO: Clinical Data for A1C and Weight Change, captured 2026-11-12](https://mounjaro.lilly.com/hcp/clinical-data#:~:text=at%20104%20weeks3-,Mounjaro%20is%20not%20indicated%20for%20weight%20loss.)

Note: SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site; the Mounjaro Prescribing Information does not describe this trial.

## Related pages
- [Medical information: Mounjaro (tirzepatide): Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/indication)
- [Safety](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/access-and-coverage)
